BriaCell Therapeutics Corp
Company Profile
Business description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Contact
235-15th Street
Suite 300, 3rd Floor, Bellevue Centre
West Vancouver
VancouverBCV7T 2X1
CANT: +1 888 485-6340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2025
Employees
12
Stocks News & Analysis
stocks
A collection of our best stock opportunities
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
stocks
Undervalued ASX share showing progress in global efforts
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,966.70 | 3.20 | 0.04% |
CAC 40 | 7,912.35 | 111.47 | 1.43% |
DAX 40 | 24,267.46 | 297.10 | 1.24% |
Dow JONES (US) | 44,837.56 | 64.36 | -0.14% |
FTSE 100 | 9,135.80 | 54.36 | 0.60% |
HKSE | 25,524.45 | 37.68 | -0.15% |
NASDAQ | 21,178.58 | 70.27 | 0.33% |
Nikkei 225 | 40,674.55 | 323.72 | -0.79% |
NZX 50 Index | 12,936.41 | 25.67 | 0.20% |
S&P 500 | 6,389.77 | 1.13 | 0.02% |
S&P/ASX 200 | 8,704.60 | 6.90 | 0.08% |
SSE Composite Index | 3,609.71 | 11.77 | 0.33% |